每年專案
個人檔案
經歷
- 2023.08- 臺北醫學大學管理學院副院長
- 2023.08- 臺北醫學大學醫務管理學系主任
- 2020 臺北醫學大學醫務管理學系教授
- 2016 臺北醫學大學醫務管理學系副教授
指紋
查看啟用 Wei Pin Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
專案
- 18 已完成
-
Evaluating the cost-effectiveness of atezolizumab-bevacizumab in advanced hepatocellular carcinoma: Insights from Taiwan
Chang, T. W., Chang, W. C., Chou, W. H., Chang, W. P. & Kuo, C. N., 2025, 於: Journal of Food and Drug Analysis. 33, 2, p. 163-171 9 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
2 引文 斯高帕斯（Scopus） -
Identifying breast cancer risk factors and evaluating biennial mammography screening efficacy using big data analysis in Taiwan
Huang, C. C., Lu, T. P., Wang, Y. J., Chen, B. F., Yang, H. T., Chang, W. P. & Tseng, L. M., 12月 2025, 於: Scientific Reports. 15, 1, 16250.研究成果: 雜誌貢獻 › 文章 › 同行評審
1 引文 斯高帕斯（Scopus） -
Cost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan
Lee, W.-L., Chou, W.-H., Chang, W.-P., Chang, T.-W., Kuo, C.-N. & Chang, W.-C., 12月 15 2024, 於: Journal of Food and Drug Analysis. 32, 4, p. 568-576 9 p., 14.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Trends in the incidence of head and neck cancer: A nationwide population-based study
Yang, T. H., Xirasagar, S., Cheng, Y. F., Chen, C. S., Chang, W. P. & Lin, H. C., 5月 2023, 於: Oral Oncology. 140, 106391.研究成果: 雜誌貢獻 › 文章 › 同行評審
14 引文 斯高帕斯（Scopus） -
Chronic obstructive pulmonary disease is associated with a higher risk of functional gastrointestinal disorders
Chiu, Y. C., Chang, W. P., Tang, G. J., Lan, T. Y., Lee, K. Y. & Su, V. Y. F., 6月 2022, 於: Respiratory Medicine. 197, 106833.研究成果: 雜誌貢獻 › 文章 › 同行評審
7 引文 斯高帕斯（Scopus）
資料集
-
Additional file 1: of Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis
Chang, Y.-H. (Creator), Li, W.-H. (Contributor), Chang, Y. (Creator), Peng, C.-W. (Creator), Cheng, C.-H. (Contributor), Chang, W.-P. (Creator) & Chuang, C.-M. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3642380_d1.v1, https://springernature.figshare.com/articles/dataset/Additional_file_1_of_Front-line_intraperitoneal_versus_intravenous_chemotherapy_in_stage_III-IV_epithelial_ovarian_tubal_and_peritoneal_cancer_with_minimal_residual_disease_a_competing_risk_analysis/4462352/1
資料集: Dataset
-
Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis
Chang, Y.-H. (Creator), Li, W.-H. (Contributor), Chang, Y. (Creator), Peng, C.-W. (Creator), Cheng, C.-H. (Contributor), Chang, W.-P. (Creator) & Chuang, C.-M. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3642380.v1, https://figshare.com/collections/Front-line_intraperitoneal_versus_intravenous_chemotherapy_in_stage_III-IV_epithelial_ovarian_tubal_and_peritoneal_cancer_with_minimal_residual_disease_a_competing_risk_analysis/3642380/1
資料集: Dataset